Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464380 | 0.89 | ABHD6 (0.48) | GPR119HRH3MGLLABHD6 | |
| SCHEMBL31574756 | 0.89 | GPR119 (0.48) | GPR119HRH3MGLLABHD6ALK | |
| SCHEMBL31574782 | 0.88 | GPR119 (0.45) | GPR119HRH3MGLLABHD6ALK | |
| SCHEMBL3579129 | 0.86 | GPR119 (0.67) | GPR119HRH3ALK | |
| SCHEMBL30426929 | 0.86 | GPR119 (0.67) | GPR119HRH3ALK | |
| SCHEMBL31753619 | 0.86 | GPR119 (0.54) | GPR119HRH3MGLLABHD6 | |
| SCHEMBL31752756 | 0.85 | GPR119 (0.51) | GPR119HRH3MGLLABHD6ALK | |
| SCHEMBL31216657 | 0.85 | GPR119 (0.51) | GPR119MGLLALKNAMPT | |
| SCHEMBL30801988 | 0.82 | GPR119 (0.48) | GPR119HRH3MGLLABHD6NAMPT | |
| SCHEMBL6475033 | 0.81 | GPR119 (0.62) | GPR119HRH3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024054603-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | GPR119 2134/4885HRH3 788/4885MGLL 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.